Valuation: Geron Corporation

Market Cap 1.01B 874M 819M 747M 1.4B 96.21B 1.43B 9.63B 3.76B 48.17B 3.79B 3.7B 161B P/E 2026 *
-37.4x
P/E 2027 * 23.1x
Enterprise Value 1.01B 874M 819M 747M 1.4B 96.21B 1.43B 9.63B 3.76B 48.17B 3.79B 3.7B 161B EV / Sales 2026 *
4.27x
EV / Sales 2027 * 2.95x
Free-Float
99.92%
Yield 2026 *
-
Yield 2027 * -
1 day+0.32%
1 week+0.96%
Current month+22.87%
1 month+11.62%
3 months+12.41%
6 months-3.94%
Current year+20.08%
1 week 1.43
Extreme 1.43
1.65
1 month 1.22
Extreme 1.22
1.65
Current year 1.08
Extreme 1.08
2.01
1 year 1.04
Extreme 1.04
2.01
3 years 1.04
Extreme 1.04
5.34
5 years 0.99
Extreme 0.9899
5.34
10 years 0.75
Extreme 0.75
6.99
Manager TitleAgeSince
Chief Executive Officer 54 2025-08-06
Director of Finance/CFO 59 2023-09-24
Chief Tech/Sci/R&D Officer - 2025-09-30
Director TitleAgeSince
Director/Board Member 76 2010-05-20
Director/Board Member 72 2012-09-27
Director/Board Member 55 2019-03-25
Date Insider Type Main position Quantity % Market Cap.
6/30/26 Free

Director

6,103 0.0010%
2/17/26 Fiscal year

Chief Financial Officer

1,724,855 0.2702%
2/17/26 Free

Chief Technology Officer

2,220,000 0.3478%
Change 5-day change 1-year change 3-year change Capi.($)
+0.32%+0.96%+10.84%-45.53% 1.01B
+2.07%+10.05%+77.41%+106.53% 70.1B
-0.60%+0.34%+37.33%+65.48% 54.93B
-3.29%-3.63%+3.96%+472.83% 28.89B
+0.04%+12.56%+54.67%+5.47% 23.9B
+0.21%+1.83%-17.66%-13.57% 23.3B
+0.35%+8.24%+252.94%+466.50% 18.41B
-0.59%+7.62%+40.52%-20.32% 18.77B
-0.57%+6.85%+30.20%+580.70% 16.1B
+0.63%-3.24%+31.23%+134.82% 12.48B
Average -0.13%+9.54%+52.14%+175.29% 26.79B
Weighted average by Cap. +0.07%+8.08%+55.21%+163.24%

Financials

2026 *2027 *
Net sales 236M 205M 192M 175M 329M 22.54B 334M 2.26B 882M 11.28B 887M 868M 37.63B 342M 296M 278M 253M 476M 32.62B 483M 3.26B 1.28B 16.33B 1.28B 1.26B 54.46B
Net income -27.18M -23.55M -22.06M -20.13M -37.84M -2.59B -38.42M -260M -101M -1.3B -102M -99.84M -4.33B 50.14M 43.44M 40.71M 37.13M 69.8M 4.78B 70.87M 479M 187M 2.39B 188M 184M 7.99B
Net Debt - -
Logo Geron Corporation
Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Employees
258
Date Price Change Volume
26-08-13 US$1.590 +1.27% 1,285,581
26-08-12 US$1.570 -3.68% 10,202,342
26-08-11 US$1.630 +10.14% 12,716,754
26-08-10 US$1.480 0.00% 5,641,719
26-08-07 US$1.480 -5.73% 8,885,551
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.570USD
Average target price
4.250USD
Spread / Average Target
+170.70%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GERN Stock